The P-III (ASCLEPIOS I/II) trials and the (ALITHIOS) OLE trial evaluating Kesimpta in patients with RMS
The results showed that 78.8% of patients treated continuously with Kesimpta achieved NEDA-3 vs 51.8% of those who switched from teriflunomide to Kesimpta in the extension phase after 4yrs. of treatment
The additional analysis from (ASCLEPIOS I/II) showed improvements in CPS vs those treated with teriflunomide. The results were based on the prior presented efficacy data from (ASCLEPIOS I/II) & (ALITHIOS) trials which demonstrated consistent differences in cumulative relapses, MRI lesion activity & risk of disability worsening b/w those who were continuously treated with Kesimpta vs those who switched at a later time
Ref: Novartis | Image: Novartis
